{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:16:40Z","timestamp":1790641000910,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017596","name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","doi-asserted-by":"publisher","award":["V-2021.3\/1503_68403\/2021\u20132022"],"award-info":[{"award-number":["V-2021.3\/1503_68403\/2021\u20132022"]}],"id":[{"id":"10.13039\/100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1310"],"award-info":[{"award-number":["CRC1310"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"BMBF Bonn","doi-asserted-by":"publisher","award":["01KX2021"],"award-info":[{"award-number":["01KX2021"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008001","name":"Universit\u00e4t zu K\u00f6ln","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Host & Microbe"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.chom.2022.07.002","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T08:07:40Z","timestamp":1657181260000},"page":"1231-1241.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns"],"prefix":"10.1016","volume":"30","author":[{"given":"Henning","family":"Gruell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Vanshylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Korenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinkus","family":"Tober-Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Zehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"M\u00fcnn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Janicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schommers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Erik","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kreer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chom.2022.07.002_bib1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1056\/NEJMc2200133","article-title":"Protection against the omicron variant from previous SARS-CoV-2 infection","volume":"386","author":"Altarawneh","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib2","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cell.2021.02.035","article-title":"Extremely potent human monoclonal antibodies from COVID-19 convalescent patients","volume":"184","author":"Andreano","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib3","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib4","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chom.2022.07.002_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chom.2022.07.002_bib6","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chom.2022.07.002_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron","volume":"602","author":"Carre\u00f1o","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2021.8828","article-title":"Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial","volume":"326","author":"Cohen","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.chom.2022.07.002_bib12","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/j.cell.2021.05.005","article-title":"Tackling COVID-19 with neutralizing monoclonal antibodies","volume":"184","author":"Corti","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/v12050513","article-title":"Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays","volume":"12","author":"Crawford","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.chom.2022.07.002_bib14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chom.2022.07.002_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/gch2.1018","article-title":"Data, disease and diplomacy: GISAID\u2019s innovative contribution to global health","volume":"1","author":"Elbe","year":"2017","journal-title":"Glob. Chall."},{"key":"10.1016\/j.chom.2022.07.002_bib16","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","article-title":"UCSF ChimeraX: meeting modern challenges in visualization and analysis","volume":"27","author":"Goddard","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.chom.2022.07.002_bib19","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/s41467-021-24435-8","article-title":"Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies","volume":"12","author":"Greaney","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2022.07.002_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","article-title":"mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant","volume":"28","author":"Gruell","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib21","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.immuni.2022.05.005","article-title":"Antibody-mediated neutralization of SARS-CoV-2","volume":"55","author":"Gruell","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.chom.2022.07.002_bib22","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib23","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chom.2022.07.002_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.chom.2022.07.002_bib25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib28","doi-asserted-by":"crossref","first-page":"eabf1906","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib30","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/nar\/gkf436","article-title":"MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform","volume":"30","author":"Katoh","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chom.2022.07.002_bib31","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","article-title":"GISAID\u2019s role in pandemic response","volume":"3","author":"Khare","year":"2021","journal-title":"China CDC Wkly."},{"key":"10.1016\/j.chom.2022.07.002_bib32","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41467-020-20602-5","article-title":"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2022.07.002_bib34","doi-asserted-by":"crossref","first-page":"110218","DOI":"10.1016\/j.celrep.2021.110218","article-title":"The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance","volume":"38","author":"Kimura","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.chom.2022.07.002_bib35","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","article-title":"Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients","volume":"182","author":"Kreer","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib36","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.cell.2020.09.049","article-title":"A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model","volume":"183","author":"Kreye","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1101\/pdb.top115","article-title":"IMGT, the international ImMunoGeneTics information system","volume":"2011","author":"Lefranc","year":"2011","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.chom.2022.07.002_bib38","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib39","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.cell.2021.06.021","article-title":"In\u00a0vitro and in\u00a0vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib40","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib41","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib42","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib43","article-title":"Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish Households","author":"Lyngse","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.chom.2022.07.002_bib44","doi-asserted-by":"crossref","first-page":"W636","DOI":"10.1093\/nar\/gkz268","article-title":"The EMBL-EBI search and sequence analysis tools APIs in 2019","volume":"47","author":"Madeira","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chom.2022.07.002_bib45","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa2119658","article-title":"Population immunity and Covid-19 severity with omicron variant in South Africa","volume":"386","author":"Madhi","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/nar\/28.1.292","article-title":"Codon usage tabulated from international DNA sequence databases: status for the year 2000","volume":"28","author":"Nakamura","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chom.2022.07.002_bib47","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chom.2020.09.002","article-title":"Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2","volume":"28","author":"Nielsen","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chom.2022.07.002_bib48","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"key":"10.1016\/j.chom.2022.07.002_bib50","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib51","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib53","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib54","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.abf4830","article-title":"Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody","volume":"371","author":"Rappazzo","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.chom.2022.07.002_bib55","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/bioinformatics\/btaa739","article-title":"CoV-AbDab: the coronavirus antibody database","volume":"37","author":"Raybould","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.chom.2022.07.002_bib56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.chom.2022.07.002_bib57","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib58","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chom.2022.07.002_bib59","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMc2119641","article-title":"Plasma neutralization of the SARS-CoV-2 omicron variant","volume":"386","author":"Schmidt","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib61","doi-asserted-by":"crossref","first-page":"30494","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","article-title":"GISAID: global initiative on sharing all influenza data - from vision to reality","volume":"22","author":"Shu","year":"2017","journal-title":"Euro Surveill."},{"key":"10.1016\/j.chom.2022.07.002_bib62","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2144\/00286ir01","article-title":"The sequence manipulation suite: JavaScript programs for analyzing and formatting protein and DNA sequences","volume":"28","author":"Stothard","year":"2000","journal-title":"BioTechniques"},{"key":"10.1016\/j.chom.2022.07.002_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01911-2","article-title":"Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa","author":"Tegally","year":"2022","journal-title":"Nat. Med"},{"key":"10.1016\/j.chom.2022.07.002_bib64","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"Tiller","year":"2008","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.chom.2022.07.002_bib65","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib66","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib67","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.chom.2021.04.015","article-title":"Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans","volume":"29","author":"Vanshylla","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chom.2022.07.002_bib68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.chom.2021.12.010","article-title":"Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers","volume":"30","author":"Vanshylla","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chom.2022.07.002_bib69","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib70","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2022.07.002_bib71","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41421-022-00401-6","article-title":"Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses","volume":"8","author":"Wang","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.chom.2022.07.002_bib72","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.chom.2020.11.012","article-title":"D614G spike mutation increases SARS CoV-2 susceptibility to neutralization","volume":"29","author":"Weissman","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chom.2022.07.002_bib74","doi-asserted-by":"crossref","first-page":"110812","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.chom.2022.07.002_bib75","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41591-022-01715-4","article-title":"Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern","volume":"28","author":"Wratil","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib76","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chom.2022.07.002_bib77","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.cell.2022.04.035","article-title":"Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike","volume":"185","author":"Yamasoba","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.chom.2022.07.002_bib78","doi-asserted-by":"crossref","first-page":"W34","DOI":"10.1093\/nar\/gkt382","article-title":"IgBLAST: an immunoglobulin variable domain sequence analysis tool","volume":"41","author":"Ye","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chom.2022.07.002_bib79","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chom.2022.07.002_bib80","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/s41467-021-24514-w","article-title":"Potent and protective IGHV3-53\/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2022.07.002_bib81","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMc2119426","article-title":"Effects of a prolonged booster interval on neutralization of omicron variant","volume":"386","author":"Zhao","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2022.07.002_bib82","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chom.2022.07.002_bib83","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","article-title":"Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein","volume":"26","author":"Zost","year":"2020","journal-title":"Nat. Med."}],"container-title":["Cell Host & Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312822003183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312822003183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:30:05Z","timestamp":1761827405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931312822003183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":83,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1931312822003183"],"URL":"https:\/\/doi.org\/10.1016\/j.chom.2022.07.002","relation":{},"ISSN":["1931-3128"],"issn-type":[{"value":"1931-3128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns","name":"articletitle","label":"Article Title"},{"value":"Cell Host & Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chom.2022.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}